Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes mortality (all‐cause) (dichotomous Peto method) compared with placebo (very low certainty).
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
It is very uncertain whether beclometasone/LABA changes mortality (all‐cause) (dichotomous Peto method) compared with LABA (very low certainty).
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at last · people with liver metastases
Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality, 6 months1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 6 months1 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with preventing morbidity and mortality in very preterm infants
Cerebral NIRS oximetry showed no clear difference in all‐cause mortality compared with no cerebral NIRS oximetry (low certainty).
1 finding from 1 review
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults in sinus rhythm after cardioversion of atrial fibrillation
Metoprolol showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality ‐ children · patients with chronic asthma
1 finding from 1 review
All‐cause mortality ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause mortality ‐ children compared with regular salbutamol (low certainty).
1 finding from 1 review
All‐cause mortality formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause mortality ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/budesonide vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
All‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).
1 finding from 1 review
Mortality (all‐cause) ‐ formoterol versus salbutamol ( · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found